| RHYTHM PHARMACEUTICALS |
| USA |
| Gesundheit |
| US76243J1051 / A2H5A0 |
| 1RV (Frankfurt) / RYTM (NASDAQ) |
| FRA:1RV, ETR:1RV, 1RV:GR, NASDAQ:RYTM |
| - |
| https://www.rhythmtx.com/ |
|
Rhythm Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases, particularly those involving hyperphagia and severe obesity. Its lead product, IMCIVREE ..
>Volltext.. |
| 6420.8 Mio. EUR |
| 6327.31 Mio. EUR |
| 205.41 Mio. EUR |
| -170.85 Mio. EUR |
| -175.81 Mio. EUR |
| -2.67 EUR |
| 93.99 Mio. EUR |
| 56.18 Mio. EUR |
| -90.2 Mio. EUR |
| 2.68 |
| 58.34% |
| -15.7% |
| - |
| - |
| - |
| 4 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 14.591.877 Euro. |
| RHYTHM PHARMACEUTICALS, RHYTHM PHARMA, RHYTHM PHARMACEUTICAL |
| 23.08.26 |
|